Display Settings:


Send to:

Choose Destination
See comment in PubMed Commons below
Boll Ist Sieroter Milan. 1990 Jun;69(2):385-90.

[Safety and immunogenicity of an anti-hepatitis-B vaccine obtained using the recombinant DNA technique: results of a longitudinal study in hospital personnel].

[Article in Italian]

Author information

  • 1Ricercatore Università di Cassino.


A prospective study of the immunogenicity, safety and persistence of antibodies induced by the DNA-recombinant anti-hepatitis B vaccine Engerix B was conducted in a risk group as health care workers. 115 health care workers were randomly allocated into two groups. Immunization was carried out according to a 0-1-6 month vaccination schedule in one group and to a 0-1-2-12 month schedule in the other group. Results indicate that the DNA-recombinant anti-hepatitis B vaccine is well tolerated and highly immunogenic. Reactogenicity to the vaccine was low in incidence and mild in severity with no significant difference appearing between the study groups.

[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Loading ...
    Write to the Help Desk